Could an allergy pill mend hearts after an attack?

NCT ID NCT06548204

Recruiting now Disease control Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine Source: ClinicalTrials.gov ↗

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This trial tests whether fexofenadine, a common allergy medication, can help the heart heal better after a severe type of heart attack called STEMI. Participants will receive either fexofenadine or a placebo for six months, alongside standard care, after undergoing a procedure to open the blocked artery. The study uses MRI scans to measure heart muscle scarring and function, aiming to see if the drug reduces damage and improves recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fexofenadine hydrochloride
What this could lead to: If effective, fexofenadine could become a simple, widely available add-on treatment to reduce heart muscle scarring and improve recovery after a heart attack.
What could go wrong: This is an early-stage trial with a modest number of participants. The drug may not reduce scarring, and its benefits might not extend beyond the specific heart attack population studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ST-elevation myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION (STEMI)

Contacts and locations

Locations

The 2nd Affiliated Hopital of Zhejiang University, School of Medicine
RECRUITING

Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.